Alirocumab
Products Alirocumab was approved in the United States and EU in 2015 and in many countries in 2016 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Structure and properties Alirocumab is an IgG1 monoclonal antibody with a molecular mass of 146 kDa. Effects Alirocumab … Alirocumab
